Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
IPO Year: 2021
Exchange: NASDAQ
Website: inspira-technologies.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $9.00 → $10.00 | Buy | Aegis Capital |
| 8/26/2021 | $9.00 | Buy | Aegis Capital |
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
F-3 - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Aegis Capital reiterated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $10.00 from $9.00 previously
Aegis Capital initiated coverage of Inspira Technologies Oxy with a rating of Buy and set a new price target of $9.00
Fastest customizable press release news feed in the world
RA'ANANA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that a top U.S. hospital, has expanded its clinical use of the INSPIRA™ ART100 system to lung transplantation procedures, one of the most demanding applications in advanced respiratory care. The hospital was included in the U.S. News & World Report 2025-2026 Best Hospitals Honor Roll of the nation's top 20 hospitals, and has multiple specialties consistently ranked among the top five nationwide. This clinical expansion follows the hospital's positive
RA'ANANA, Israel, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, has received U.S. Patent approval for low flow rates extracorporeal oxygenation system and methods of use. This patent represents the core technology of the ART500 device, a key asset in the Company's strategy to penetrate the $20 billion estimated market for advanced respiratory support. This innovation has 16 claims found to be novel. The patent provides further protection for the underlying core technology of Inspira's ART500 system, which is designed to provide ex
RA'ANANA, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that a national ministry of health in Africa (the "Ministry of Health") has placed a $27 million binding purchase order for Inspira's FDA-cleared ART100 systems. The purchase order, secured through Inspira's exclusive distribution partner, dedicated solely to the commercialization of Inspira's products, initiates an immediate nationwide deployment program. The purchase order provides for full contractual payment scheduled for completion during 2025.
RA'ANANA, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has filed a shelf registration statement on Form F-3 (File No. 333-289324) with the U.S. Securities and Exchange Commission on August 6, 2025, as part of a routine shelf renewal process conducted every three years. This updated filing replaces the Company's previous shelf registration statement, which is set to expire on August 18, 2025. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing
RA'ANANA, Israel, July 31, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has activated a leading consulting firm to accelerate high-impact execution across strategic expansion, partner engagement, and advanced structuring pathways already in motion. The consulting firm is a specialized group that partners with biotech and medtech companies at critical inflection points. The firm's expertise lies in structuring and leading the execution of high-value strategic transactions, accelerating commercial growth, and transfo
RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. The notice, dated July 17, 2025, stated that for the 10 consecutive business days from July 2, 2025, through July 16, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, Inspira has s
RA'ANANA, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW)) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously announced by the Company on July 7, 2025, establishing a definitive pathway for the nationwide adoption of the Company's ART100 system and creating the foundation for a future global scale-up. This breakthrough follows a direct invitation from the govern
RA'ANANA, Israel, July 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational component of the national emergency infrastructure and to establish a global distribution framework. The meeting, scheduled for July 8, 2025, is intended to define the key terms and roadmap for this strategic collaboration. These advance
RA'ANANA, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, representing a major commercial inflection point for the Company. The order was placed by a privately held company headquartered outside the United States, in a global strategic hub, with an established track record and active commercial ties to both government entities and institutional healthcare customers. Under the terms of the binding purchase order, full pay
RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation. The ART100 system has been successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months. Details of specific hospital deployments are subject to confidentiality, but reflect Tier-
Live Leadership Updates
Inspira Technologies* advancement of its AI-powered blood monitoring technology comes amid robust growth in medical technology M&A, with Q3 2024 seeing 275 deals worth $34 billion - a 35% increase year-over-year. The integration of this new oxygenation indicator strengthens the Company's position in both the $2.5 billion blood gas analysis market and, through the FDA-cleared INSPIRA ART100 system, the $19 billion mechanical ventilation market. With clinical evaluations of the HYLA blood sensor underway at Sheba Medical Center and preliminary results reportedly expected in the near future, the Company continues to execute its strategy of combining AI-enhanced monitoring capabilities with inn
RA'ANANA, Israel, Jan. 21, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, has announced the appointment of Mr. Tal Parnes as the new chairman of the board of directors, effective February 1, 2025. Mr. Parnes brings a wealth of experience and expertise to his new role at Inspira. With a distinguished career spanning over three decades in the technology sector, with a special focus in the medical technology and pharmaceutical industries, Mr. Parnes has consistently demonstrated exceptional leadership and strategic vision. As a serial entrepreneur, Parnes has demonstrated
RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board. Dr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the
Dr. Nir is a clinical strategy expert with market experience RA'ANANA, Israel, May 30, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer ("CMO"). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company. As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira's medical operations and strategic initiatives. With an unwavering commitment to patient care, inn
RA'ANANA, Israel, Aug. 10, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company"), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, today announced the appointment of Lior Amit, CPA, to the Company's board of directors. Mr. Amit has extensive business and go-to-market experience to further support Inspira's planned future deployment and market penetration of the Augmented Respiration Technology (ART) system. For more than 17 years, Mr. Amit served as the CFO of the BBR Saatchi & Saatchi advertising group in Israel, playing a vital role in the
This live feed shows all institutional transactions in real time.
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
SC 13G - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)
Live finance-specific insights
Significant progress in HYLA blood sensor and INSPIRA ART core technologies RA'ANANA, Israel, March 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2024, and provided a corporate update. Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: "2024 was a transformative year for Inspira, marked by significant technological advancements and a major regulatory milestone. We successfully obtained 510(k) clearance from the Food and Drug Administration ("FDA") for our INSPIRA™ ART100 system an
Company to aggressively promote INSPIRA™ ART100 in the U.S. and additional markets following FDA clearance, as well as accelerate plans for ground-breaking INSPIRA™ ART (Gen2) RA'ANANA, Israel, June 20, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN), (NASDAQ:IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President and co-founder, Mr. Joe Hayon, presented a business plan with targets for the Company's next-generation technologies on a Company conference call today. On the call, Inspira unveiled plans to build an opportunity for a share of the $19 billion mechanical ventilation market. Inspira's
The event is an opportunity to present and demonstrate new products and technologies to potential customers and strategic partners RA'ANANA, Israel, June 5, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, is proud to announce plans to exhibit the INSPIRA™ ART100 System, recently cleared by the U.S. Food and Drug Administration ("FDA"), at the Extracorporeal Life Support Organization (ELSO) conference in Detroit, Michigan between September 29 to October 1, 2024. This event provides the Company with an opportunity to present the system in front of healthcare representa
RA'ANANA, Israel, May 30, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) (the "Company" or "Inspira") a breakthrough medical technology company, announced today that Company President, Director, and co-founder, Mr. Joe Hayon, will discuss the Company's business targets, distribution agreements and next steps in a conference call to be held at 9:00am Eastern Time on Thursday, June 20, 2024. This follows the significant milestone of receiving FDA clearance for the INSPIRA™ ART100 system, as announced on May 28, 2024. Event Details: Date: Thursday, June 20, 2024 Time: 9:00 am Eastern Time Speaker: Joe Hayon, President, Director, and Co-Founder Attendance Info
FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, commented, "In 2023, we achieved significant progress in diversifying our business development to ensure continuous growth, reaching very important milestones that we believ
The major milestone refers to Inspira's proprietary technology to oxygenate blood for the INSPIRA™ ART (Gen 2). This patented tech is considered by Inspira to be a game-changer and also aims to replace technologies used today by current medical device companies.Anticipated U.S. Food and Drug Administration (FDA) Clearance for INSPIRA™ ART100 (Gen 1) in the first half of 2024, to address the $1.16 Billion perfusion systems market.RA'ANANA, Israel, March 4, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, announced today that the Company's President, and co-founder, Mr. Joe Hayon, p
RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, announced today that the Company President, Director and co-founder, Mr. Joe Hayon, will present an Investor Presentation and announce the Company's next major milestone. The conference call is to be held at 9:00am Eastern Time on Monday, March 4, 2024. To attend the conference call, please enter: link Inspira Technologies OXY B.H.N. Ltd. Inspira™ Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Re
ORLANDO, FL / ACCESSWIRE / May 5, 2023 / RedChip Companies will air new interviews with Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW))) and Genius Group Limited (NYSE:GNS) on The RedChip Money Report® on Bloomberg TV, this Saturday, May 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Inspira Technologies: https://www.redchip.com/assets/iinn_interview_accessGenius Group: https://www.geniusuinfo.com/interview_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experien
ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Interview Highlights: In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President, Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading medi
ORLANDO, FL / ACCESSWIRE / December 22, 2022 / RedChip Companies will air a new interview with Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Interview highlights:In the exclusive RedChip Money Report interview, Inspira™ Technologies' Co-Founder & President Joe Hayon discusses how Inspira's technology could reduce the need for invasive mechanical ventilation, plans to begin human studies at leading m